<?xml version='1.0' encoding='utf-8'?>
<ns0:TEI xmlns:ns0="http://www.tei-c.org/ns/1.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:space="preserve" xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd">
	<ns0:teiHeader xml:lang="en">
		<ns0:fileDesc>
			<ns0:titleStmt>
				<ns0:title level="a" type="main">2022 American College of Rheumatology (ACR) Guideline for Vaccinations in Patients with Rheumatic and Musculoskeletal Diseases</ns0:title>
			</ns0:titleStmt>
			<ns0:publicationStmt>
				<ns0:publisher />
				<ns0:availability status="unknown"><ns0:licence /></ns0:availability>
			</ns0:publicationStmt>
			<ns0:sourceDesc>
				<ns0:biblStruct>
					<ns0:monogr>
						<ns0:imprint>
							<ns0:date />
						</ns0:imprint>
					</ns0:monogr>
					<ns0:idno type="MD5">D064A5AD64D848FEC553AA8136BD6112</ns0:idno>
					<ns0:idno type="DOI">10.1002/acr.25045</ns0:idno>
				</ns0:biblStruct>
			</ns0:sourceDesc>
		</ns0:fileDesc>
		</ns0:teiHeader>
	<ns0:text xml:lang="en">
		<ns0:body><ns0:div><ns0:head>Conclusion:</ns0:head><ns0:p>Application of these recommendations should take into consideration patients' individual risk for vaccine-preventable illness and for disease flares, particularly if immunosuppressive medications are held for vaccination. Shared decision-making with patients is encouraged in clinical settings.</ns0:p></ns0:div><ns0:div><ns0:head>Expanded indications for specific vaccines in patients with RMDs on immunosuppression</ns0:head><ns0:p>For RMD patients aged ≥ 65 years, and RMD patients aged &gt;18 and &lt;65 years who are on immunosuppressive medication, giving high-dose or adjuvanted influenza vaccination is conditionally recommended over giving regular-dose influenza vaccination.</ns0:p><ns0:p>For patients with RMD aged &lt;65 years who are on immunosuppressive medication, pneumococcal vaccination is strongly recommended.</ns0:p><ns0:p>For patients with RMD aged &gt;18 years who are on immunosuppressive medication, administering the recombinant zoster vaccine is strongly recommended.</ns0:p><ns0:p>For patients with RMD aged &gt;26 and &lt;45 years who are on immunosuppressive medication and not previously vaccinated, vaccination against HPV is conditionally recommended.</ns0:p></ns0:div><ns0:div><ns0:head>Revised February 24, 2023</ns0:head><ns0:p>Whether to give multiple vaccinations to RMD patients on the same day For RMD patients, giving multiple vaccinations on the same day rather than giving each individual vaccination on a different day is conditionally recommended.</ns0:p></ns0:div><ns0:div><ns0:head>Medication management at the time of non-live attenuated vaccine administration</ns0:head></ns0:div></ns0:body><ns0:back>
			<ns0:div type="annex">
<ns0:div><ns0:head>Immunosuppressive medication management at the time of live-attenuated virus vaccine administration</ns0:head><ns0:p>For RMD patients who are on immunosuppressive medication, deferring live-attenuated vaccines is conditionally recommended.</ns0:p><ns0:p>For RMD patients, holding immunosuppressive medication for an appropriate period before (see JAK= Janus kinase; TNF=tumor necrosis factor; IL=interleukin; IVIG= intravenous immunoglobulin G; IV = intravenous a for patients taking the equivalent of prednisone &lt; 20 mg/day or &lt; 2 mg/kg/day for patients weighing &lt; 10 kg, or alternate-day glucocorticoid therapy (i.e., "low level immunosuppression" (14, 68), these low doses can be continued if vaccination is critical and the risk of a disease flare or adrenal insufficiency off glucocorticoids is high. b for patients taking methotrexate ≤ 0.4 mg/kg/week or azathioprine ≤ 3 mg/kg/day ("low level" immunosuppression" (14, 68), hold times can be shortened if vaccination is critical and the risk of a disease flare off immunosuppression is high. c for medications with more than one FDA-approved dosing interval, the longest interval should be chosen (e.g., hold subcutaneous adalimumab for 2 weeks although it can be dosed every 1 or every 2 weeks). d In children with autoinflammatory disorders or systemic juvenile idiopathic arthritis in whom the risk of disease flare if biologic DMARDs are held is very high, shorter hold times can be considered if live-attenuated vaccination is critical. e the recommendation to hold IVIG prior to vaccination is designed to enhance vaccine efficacy, not safety. In some situations, such as during a measles outbreak, earlier vaccination would be preferred over delay. </ns0:p></ns0:div>
<ns0:div><ns0:head>When to administer live-attenuated rotavirus vaccination to infants exposed to immunosuppressive medications in utero</ns0:head></ns0:div>			</ns0:div>
			<ns0:div type="references">

				</ns0:div>
		</ns0:back>
	</ns0:text>
</ns0:TEI>